FindMyKOL
Clinical trialNCT00464620CompletedPhase 2Interventional

Trial of Dasatinib in Advanced Sarcomas

NCT00464620 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. As of 21 Nov 2026, it is completed. It studies Dasatinib in Chondrosarcoma, Chordoma and 8 more conditions. The registry lists an enrollment of 366 participants at 20 sites in 1 country. The registry lists a start date of 31 May 2007 and a primary completion date of 31 Dec 2016. One of its registered investigators has a FindMyKOL profile.

SponsorSarcoma Alliance for Research through Collaboration →Enrollment366ChondrosarcomaChordomaEpithelioid SarcomaGastrointestinal Stromal Tumor (GIST)Giant Cell Tumor of BoneHemangiopericytoma+4 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00464620
FieldValue
Registry IDNCT00464620
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorSarcoma Alliance for Research through Collaboration
Enrollment366
Registered sites20
Countries1
ConditionsChondrosarcoma, Chordoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST), Giant Cell Tumor of Bone, Hemangiopericytoma and 4 more conditions
DrugsDasatinib
Start31 May 2007
Primary completion31 Dec 2016
Study completion31 May 2017
Last update posted23 Nov 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arkansas, United States1 site
  • Arkansas Children's Hospital

    Little Rock

California, United States4 sites
  • City of Hope

    Duarte

  • Cedars-Sinai Outpatient Cancer Center

    Los Angeles

  • Stanford University

    Palo Alto

  • Sarcoma Oncology Center

    Santa Monica

District of Columbia, United States1 site
  • Washington Cancer Institute

    Washington D.C.

Georgia, United States1 site
  • Winship Cancer Institute at Emory University

    Atlanta

Idaho, United States1 site
  • Kootenai Cancer Center

    Coeur d'Alene

Illinois, United States1 site
  • Oncology Specialists

    Park Ridge

Indiana, United States1 site
  • Indiana University Cancer Center

    Indianapolis

Iowa, United States1 site
  • University of Iowa Hospitals and Clinics

    Iowa City

Maryland, United States1 site
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore

Massachusetts, United States2 sites
  • Dana Farber Cancer Institute

    Boston

  • Massachusetts General Hospital

    Boston

Michigan, United States1 site
  • University of Michigan

    Ann Arbor

Nebraska, United States1 site
  • Nebraska Methodist Hospital

    Omaha

Pennsylvania, United States3 sites
  • Fox Chase Cancer Center

    Philadelphia

  • Pennsylvania Oncology Hematology Associates

    Philadelphia

  • University of Pittsburgh Cancer Institute

    Pittsburgh

Texas, United States1 site
  • Md Anderson

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusetts: 2 sitesMA2Rhode IslandRIOregonORIdaho: 1 siteID1South DakotaSDIowa: 1 siteIA1Illinois: 1 siteIL1Indiana: 1 siteIN1OhioOHPennsylvania: 3 sitesPA3New JerseyNJConnecticutCTCalifornia: 4 sitesCA4NevadaNVWyomingWYNebraska: 1 siteNE1MissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansas: 1 siteAR1TennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexas: 1 siteTX1FloridaFLDistrict of Columbia: 1 siteDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00464620

Each answer restates registry values shown on this page.

What is NCT00464620?

NCT00464620 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. It studies Dasatinib in Chondrosarcoma, Chordoma and 8 more conditions.

Who leads NCT00464620?

The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan) as the overall official.

Where does NCT00464620 run?

The registry lists 20 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00464620 study?

The registered drug and biological interventions are Dasatinib.

When did NCT00464620 end?

The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 May 2017. The sponsor last updated the record on 23 Nov 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.